Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease - A Look to the Future of Treatment
Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease - A Look to the Future of Treatment is organized by Physicians' Education Resource, LLC (PER).
Release Date: April 28, 2023
Expiration Date: April 28, 2024
Description:
Meibomian gland dysfunction (MGD) is recognized as one of the most common causes of dry eye disease (DED). This condition can be managed with several potential treatment options that include tear replacement, clinical procedures, and pharmacologic therapies. No pharmacologic treatments are specifically FDA-approved for MGD-associated DED as of spring 2023, but options may soon expand with novel agents on the horizon.
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a live CE theater presented at SECO 2023, held in March. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with MGD, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Recognize the impact MGD-associated DED has on patients’ quality of life
• Analyze key trial data and real-world evidence surrounding current treatments for MGD-associated DED
• Review the mechanisms of action of emerging agents being evaluated for the treatment of MGD-associated DED
• Evaluate key clinical trial data for emerging agents being studied for the potential treatment of MGD-associated DED.